Citation

Migone P. Psicoterapia e Scienze Umane 2015; 49(4): 589-594.

Copyright

(Copyright © 2015)

DOI

10.3280/PU2015-004003

PMID

unavailable

Abstract

On September 16, 2015, the British Medical Journal (BMJ) published the reanalysis, authored by Le Noury et al., of the infamous "Study 329", i.e., the randomized controlled trial (RCT) by Keller et al. of 2001 on the effects of paroxetine and imipramine for major depression in adolescents, that had concluded that paroxetine was "generally well tolerated and effective". This reanalysis, instead, on the basis of the same data has reached the opposite conclusion, i.e., that paroxetine is not effective in the treatment of major depression in adolescents, and there is a clinically significant increase in harms, including serious, severe, and suicide related adverse events. The manufacturer of paroxetine, the GlaxoSmithKline (GSK) pharmaceutical company, had in fact been sued for fraud and had to pay a $3 billion fine. Copyright © FrancoAngeli.

Language: it

Keywords

Paroxetine; Fraud; Drug research; GlaxoSmithKline (GSK); Pharmaceutical companies